Resumo

WILLS, Beatriz; PRADA, Leidy P.; RINCON, Alejandra  e  BUITRAGO, Andrés F.. Dual angiotensin receptor and neprilysin inhibition (ARNI): an alternative for patients with cardiac failure. Rev. Colomb. Cardiol. [online]. 2016, vol.23, n.2, pp.120-127. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2015.08.001.

Cardiac failure (CF) is the most common cause of hospital admission in adults all over the world. In addition to its important prevalence, CF presents a high mortality rate. It is estimated that approximately 59% of patients with CF die within 5 years after the admission. This has been the motivation for the development of new, safe and effective therapies aimed at the management of this disease. LCZ696 is an angiotensin II receptor-neprilysin inhibitor; phase III studies have shown it decreases the primary outcome of cardiovascular death and admission due to worsening of the CF and global death. LCZ696 could probably become the cornerstone of the management of patients with CF with depressed ejection fraction.

Palavras-chave : Cardiac failure; natriuretic peptides; angiotensin I receptor antagonists.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )